iSERA Lifesciences Other Announcement
iSERA Lifesciences filed its Monitoring Agency Report for the Rights Issue proceeds utilization for the quarter ended June 30, 2026.
- Value
- ₹8.08 Cr
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
iSERA Lifesciences filed its Monitoring Agency Report for the Rights Issue proceeds utilization for the quarter ended June 30, 2026.
iSERA Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per SEBI regulations.
iSERA Lifesciences is exempt from SEBI related party disclosure requirements for March 2026. Its capital and net worth remain below mandatory reporting thresholds.
Covidh Technologies Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The Registrar and Share Transfer Agent, Skyline Financial Services, confirmed that no physical shares were received for dematerialisation during the quarter. This is a routine regulatory filing.